Overview

Safety and Efficacy of Two Doses of SP-8203 in Patients With Ischemic Stroke Requiring rtPA

Status:
Completed
Trial end date:
2017-08-22
Target enrollment:
Participant gender:
Summary
The current study aims to evaluate the safety of SP-8203, designing in two stages (stage-1, stage-2) to evaluate the safety and efficacy of the combination therapy of SP-8203 and rtPA for the occurrence of cerebral hemorrhage in patients with acute ischemic stroke receiving rtPA standard of care.
Phase:
Phase 2
Details
Lead Sponsor:
Shin Poong Pharmaceutical Co. Ltd.
Treatments:
Otaplimastat